Bee Venom Peptide Melittin Paralyzes Cervical Cancer Cells at the Molecular Level

…

The choice of melittin as a subject for anticancer investigation rests on a long history of observations that honeybee venom, despite its obvious toxicity to normal tissues, contains peptide components with striking selectivity for transformed cells. Melittin is a small, cationic, amphiphilic molecule whose positive charge favors electrostatic attraction to the negatively charged surfaces of tumor cell membranes, which are enriched with phosphatidylserine, glycosaminoglycans, and other anionic species that are comparatively scarce on the outer leaflet of healthy resting cells. This electrochemical preference is one of the principal reasons researchers have persisted with melittin despite its hemolytic tendencies, and it provides a plausible physical basis for the rapid onset of cytotoxicity observed in the U14 murine cervical cancer model, where exposure times as short as twenty minutes were sufficient to produce profound losses of viability. The brevity of that exposure window is itself informative, because it suggests that the earliest lethal events occur at the plasma membrane rather than requiring slow intracellular accumulation of the peptide, a pattern consistent with the membranolytic mechanism that the scanning electron microscopy findings corroborated.

The ultrastructural evidence of membrane perforation and morphological collapse deserves careful interpretation in light of the flow cytometry data. Annexin V staining detects the externalization of phosphatidylserine, an event classically associated with apoptosis but also reproducible in necrotic death when membrane integrity fails, while propidium iodide entry marks loss of plasma membrane barrier function. The observation that the Annexin V-positive and propidium iodide-positive population rose together in a dose-dependent fashion is therefore compatible with cells progressing from early apoptotic signaling into late apoptosis with secondary membrane rupture, but it is equally compatible with primary necrotic lysis in which phosphatidylserine flips to the outer leaflet as an epiphenomenon of membrane disorganization. The authors of the study appropriately acknowledged this ambiguity, and it remains one of the central unresolved questions in melittin pharmacology: whether the peptide kills tumor cells primarily by punching pores in their membranes or whether sublytic concentrations first trigger organized apoptotic programs that only later culminate in membrane failure. Distinguishing between these possibilities would require time-resolved assays of caspase activation, mitochondrial membrane potential, and cytochrome c release performed at concentrations below the lytic threshold, and such experiments would materially inform whether melittin or its derivatives could be developed as pro-apoptotic therapeutics rather than as nonspecific membrane-disrupting agents.

The transcriptomic dimension of the study adds a layer of molecular context that phenotypic assays alone cannot supply. By profiling gene expression after melittin treatment, the investigators were able to observe not merely that cells died but which cellular systems collapsed first and most dramatically. The finding that ribosomal biogenesis genes were globally suppressed is noteworthy because ribosome production is among the most energy-intensive processes in proliferating cells, and its suppression is a recognized hallmark of nucleolar stress. When ribosomal assembly is disrupted, the nucleolus releases factors that stabilize p53 and initiate cell cycle arrest or apoptosis, and although the U14 line used here is a murine model whose p53 status would need to be verified, the transcriptional signature of ribosomal shutdown is consistent with a cell that has lost the capacity to sustain protein synthesis. Similarly, the coordinated downregulation of mitochondrial oxidative phosphorylation genes suggests that melittin treatment deprived cells of their primary ATP-generating machinery, which would compound the energetic cost of attempting to repair a perforated plasma membrane. The coupling of these two metabolic catastrophes, impaired protein synthesis and impaired respiration, creates a situation from which recovery is essentially impossible, and this may explain why even brief exposures produced durable losses of colony-forming ability in the seven-day clonogenic assay.

The downregulation of Etv2, a transcription factor best known for its role in specifying endothelial and vascular lineages during embryonic development, opens an intriguing line of speculation regarding melittin’s possible effects on the tumor microenvironment. Cervical tumors, like most solid malignancies, depend on angiogenesis for sustained growth beyond a few cubic millimeters, and transcriptional programs that suppress vascular development genes within tumor cells could theoretically impair paracrine signaling to endothelial cells or reduce the tumor’s capacity to support vascular mimicry. It must be emphasized that a single-cell-line transcriptomic experiment cannot establish an anti-angiogenic effect in vivo, and the connection between Etv2 suppression in U14 cells and any measurable change in blood vessel formation remains hypothetical. Nevertheless, the observation is consistent with earlier reports that melittin-containing preparations, including purified peptide and bee venom itself, can inhibit angiogenesis in experimental models, and it suggests a mechanism by which melittin might exert indirect antitumor effects beyond direct cytotoxicity.

The pronounced upregulation of Jun, Fos, and Fosb points to activation of the AP-1 transcriptional complex, a collection of dimeric transcription factors assembled from Jun and Fos family members that coordinate cellular responses to stress, proliferation signals, and differentiation cues. AP-1 activation in the context of melittin treatment is most plausibly interpreted as a stress response, since membrane damage, oxidative stress, and metabolic collapse are all canonical triggers of JNK and p38 mitogen-activated protein kinase signaling, which converge on AP-1. However, AP-1 is a context-dependent regulator whose effects range from promoting apoptosis to driving proliferation and invasion depending on the composition of the dimer, the duration of activation, and the cooperating transcription factors available in a given cell type. The sustained or excessive activation of AP-1 in a cell already committed to death may simply be a transcriptional echo of the stress response rather than a causal driver of the phenotype, and disentangling cause from consequence would require perturbation experiments in which AP-1 activity is pharmacologically or genetically inhibited prior to melittin exposure.

Several methodological considerations frame the interpretation of these findings. The U14 cell line is a murine cervical cancer model originally derived from carcinogen-induced tumors in mice, and while it has been used extensively in preclinical cervical cancer research, its genomic and transcriptomic characteristics differ in important respects from human HPV-positive cervical carcinomas, which are driven by the E6 and E7 oncoproteins of high-risk papillomavirus types. The authors noted that prior work has shown melittin can downregulate HPV E6 and E7 expression, which would be a mechanism of particular relevance to human disease but which cannot be directly assessed in a murine line lacking those viral oncogenes. Translating the present findings into a human context will therefore require validation in HPV-positive cell lines such as HeLa, SiHa, or CaSki, and ultimately in organoid models or patient-derived xenografts that preserve the genomic heterogeneity of clinical tumors.

The reuse of a previously generated transcriptomic dataset, combined with newly acquired phenotypic data, is an efficient research strategy but also introduces the possibility that the RNA sequencing and the viability, migration, and ultrastructure assays were not performed under strictly identical conditions. Differences in passage number, confluence, serum conditions, or timing between the original sequencing experiment and the new phenotypic work could introduce batch effects that complicate the integration of transcriptional and phenotypic observations. The selection of four micrograms per milliliter as the intervention concentration was justified by the dose-response data, but transcriptomic profiles at a single concentration capture a snapshot of one point in a dynamic process, and earlier or later time points might reveal additional regulatory programs, such as inflammatory signaling, immune-related gene induction, or DNA damage response pathways, that are not visible at the chosen sampling time.

From a therapeutic development standpoint, the central obstacle to melittin’s clinical use has always been its nonspecific lytic activity against normal cells, particularly erythrocytes, which express sufficient anionic surface charge to bind the peptide and undergo hemolysis at concentrations not far above those needed to kill tumor cells in vitro. Various strategies have been explored to narrow this therapeutic window, including conjugating melittin to tumor-targeting antibodies or nanoparticles, engineering the peptide to remain inactive in circulation and activate only in the tumor microenvironment, and synthesizing analogues with reduced hemolytic potency but retained cytotoxicity toward malignant cells. The transcriptomic framework described in this study could assist such efforts by identifying downstream molecular markers, such as ribosomal stress signatures or AP-1 activation patterns, that could serve as pharmacodynamic biomarkers to confirm target engagement in future preclinical and clinical studies without relying solely on membrane damage as a readout.

The public health context motivating this research is substantial. Cervical cancer remains a leading cause of cancer mortality among women in low- and middle-income countries, where screening coverage is limited and access to HPV vaccination is uneven. Even in settings with robust vaccination programs, a generation will pass before herd immunity substantially reduces incidence among women already exposed to the virus, and therapeutic options for recurrent or metastatic disease remain limited, with immune checkpoint inhibitors benefiting only a minority of patients at considerable cost. Natural products and their derivatives have historically been a productive source of anticancer drugs, and venom-derived peptides represent a largely untapped chemical space with mechanisms of action distinct from those of conventional cytotoxic agents. The present study contributes to this field by providing a systematic, if preliminary, molecular map of how melittin perturbs cervical cancer cells, linking physical membrane disruption to metabolic collapse and specific transcriptional responses, and thereby offering a foundation upon which more targeted and less toxic melittin-based therapeutics might eventually be designed.

Future work building on these findings would benefit from several extensions. Dose-response and time-course transcriptomic experiments could delineate the temporal sequence of molecular events, distinguishing primary effects of membrane interaction from secondary consequences of metabolic failure. Proteomic and metabolomic profiling would complement the RNA-level view by revealing changes in protein abundance and metabolic flux that transcriptomics alone cannot capture. In vivo studies in immunocompetent mouse models of cervical cancer would be essential to determine whether the anti-angiogenic and cytotoxic effects observed in vitro translate into tumor regression, and whether the immune system contributes to or modulates melittin’s antitumor activity in a living organism. Finally, comparative studies across a panel of cervical cancer cell lines with differing HPV status, p53 function, and drug resistance profiles would clarify which molecular contexts predict sensitivity to melittin, moving the field toward the kind of biomarker-driven patient selection that has transformed the clinical utility of other targeted agents.

Subject of Research: cervical cancer

Article Title: Exploratory transcriptomic profiling of melittin’s efficacy in the treatment of murine cervical cancer cells

Article References: Jiang, J., Zhang, Y., Wang, M., Zhang, R., Li, Y., Qiu, J., Chen, D., Yan, T., Guo, R., & Liu, Y. (2026). Exploratory transcriptomic profiling of melittin’s efficacy in the treatment of murine cervical cancer cells. Frontiers in Cell and Developmental Biology, 14, Article 1975665. https://doi.org/10.3389/fcell.2026.1975665

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.1975665

Keywords: melittin, cervical cancer, bee venom, transcriptomics, AP-1, cancer biology, Exploratory, transcriptomic, profiling, efficacy, treatment, murine